Head and Neck Squamous Cell Carcinoma (HNSCC) Withdrawn Phase 1 / 2 Trials for DB00002 (Cetuximab)

Also known as: Head and Neck Squamous Cell Carcinoma

IndicationStatusPhase
DBCOND0043665 (Head and Neck Squamous Cell Carcinoma (HNSCC))Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02143622Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma PatientsTreatment